-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Changes in the pharmaceutical industry have attracted much attention in the industry
.
Recently, another batch of pharmaceutical companies made layoff decisions: Biogen announced layoff-related matters to some employees in the United States; Dongpei Pharmaceuticals basically disbanded its sales team in China; Gilead plans to lay off 114 employees in Morris Plains, New Jersey.
.
.
.
.
.
Bojian-related news said that Bojian had notified some employees in the United States about layoffs on Wednesday
.
The layoffs are related to the controversial approval of the Alzheimer's drug Aduhelm, which is part of a cost-cutting plan that Biogen has implemented since December 2021.
The company expects to save $500 million a year
.
It is reported that Biogen has confirmed that it may lay off about 10% of its employees
.
Another report said that Bojian has now laid off more than 100 employees, two-thirds of which are commercial teams with Alzheimer's disease franchises
.
Aduhelm is the first new drug for Alzheimer's disease approved by the FDA in the past 20 years
.
In this regard, Biogen decided to reduce the price of Aduhelm in the United States by about half
.
But access to the drug is still limited, and Biogen's sales were only $300,000 in the first quarter of 2022
.
Gilead announced on March 9 that Gilead issued a relevant layoff notice and will lay off 114 employees in Morris Plains, New Jersey
.
And the layoffs will be carried out in stages, with the layoffs planned in April, September and December respectively
.
The first batch of layoffs is scheduled for April 22
.
It is understood that the layoff was due to the disappointment of investors with the Phase III clinical data of Trodelvy, the world's first Trop-2 ADC drug acquired by the company for 11.
3 billion yuan in 2013
.
Trodelvy Phase III clinical data showed a statistically significant improvement in progression-free survival (PFS) compared to physician-chosen chemotherapy
.
Currently, Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer
.
The safety and efficacy of this indication have not been established
.
Dongpei Pharmaceuticals Dongpei Pharmaceuticals disclosed earlier this year that the company has stopped promoting its Senaijiming eye drops (Ouxiwei) in China, and has basically disbanded its sales team in China
.
However, the company still retains a small number of medical department personnel.
If the hospital needs to use Ouxiwei, it will be provided by Dongpei Pharmaceutical for one-time distribution
.
In addition to the Chinese market, the Italian and American markets are also its main strategic positions.
The company's main focus areas are ophthalmology, transplantation, oncology and metabolism
.
Adaptive Adaptive announced on Wednesday that it will lay off about 12% of its 100 employees, and the company is also undergoing a wide-ranging restructuring that will "de-prioritize" with "minimal residual disease" and immunization.
Items unrelated to the new focus on drugs
.
It is reported that the company’s layoffs are related to increasing market challenges
.
In addition to the above-mentioned pharmaceutical companies, Zymeworks, for example, has also decided to lay off half of its executives this year and lay off at least 25% of its employees by the end of 2022, considering the reduction in cash reserves and the need to reduce costs
.
From the perspective of the pharmaceutical market environment, as the competition in the entire market becomes more and more fierce, pharmaceutical companies have to adjust their business, and the accompanying wave of layoffs is also more and more fierce, not only small companies with weak viability, but also large companies
.
From the perspective of the industry, the trend of layoffs by pharmaceutical companies has just begun
.
Through layoffs, some pharmaceutical companies may be able to quickly reduce operating costs and focus on more core businesses, thus entering a relatively healthy and stable development state
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Recently, another batch of pharmaceutical companies made layoff decisions: Biogen announced layoff-related matters to some employees in the United States; Dongpei Pharmaceuticals basically disbanded its sales team in China; Gilead plans to lay off 114 employees in Morris Plains, New Jersey.
.
.
.
.
.
Bojian-related news said that Bojian had notified some employees in the United States about layoffs on Wednesday
.
The layoffs are related to the controversial approval of the Alzheimer's drug Aduhelm, which is part of a cost-cutting plan that Biogen has implemented since December 2021.
The company expects to save $500 million a year
.
It is reported that Biogen has confirmed that it may lay off about 10% of its employees
.
Another report said that Bojian has now laid off more than 100 employees, two-thirds of which are commercial teams with Alzheimer's disease franchises
.
Aduhelm is the first new drug for Alzheimer's disease approved by the FDA in the past 20 years
.
In this regard, Biogen decided to reduce the price of Aduhelm in the United States by about half
.
But access to the drug is still limited, and Biogen's sales were only $300,000 in the first quarter of 2022
.
Gilead announced on March 9 that Gilead issued a relevant layoff notice and will lay off 114 employees in Morris Plains, New Jersey
.
And the layoffs will be carried out in stages, with the layoffs planned in April, September and December respectively
.
The first batch of layoffs is scheduled for April 22
.
It is understood that the layoff was due to the disappointment of investors with the Phase III clinical data of Trodelvy, the world's first Trop-2 ADC drug acquired by the company for 11.
3 billion yuan in 2013
.
Trodelvy Phase III clinical data showed a statistically significant improvement in progression-free survival (PFS) compared to physician-chosen chemotherapy
.
Currently, Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer
.
The safety and efficacy of this indication have not been established
.
Dongpei Pharmaceuticals Dongpei Pharmaceuticals disclosed earlier this year that the company has stopped promoting its Senaijiming eye drops (Ouxiwei) in China, and has basically disbanded its sales team in China
.
However, the company still retains a small number of medical department personnel.
If the hospital needs to use Ouxiwei, it will be provided by Dongpei Pharmaceutical for one-time distribution
.
In addition to the Chinese market, the Italian and American markets are also its main strategic positions.
The company's main focus areas are ophthalmology, transplantation, oncology and metabolism
.
Adaptive Adaptive announced on Wednesday that it will lay off about 12% of its 100 employees, and the company is also undergoing a wide-ranging restructuring that will "de-prioritize" with "minimal residual disease" and immunization.
Items unrelated to the new focus on drugs
.
It is reported that the company’s layoffs are related to increasing market challenges
.
In addition to the above-mentioned pharmaceutical companies, Zymeworks, for example, has also decided to lay off half of its executives this year and lay off at least 25% of its employees by the end of 2022, considering the reduction in cash reserves and the need to reduce costs
.
From the perspective of the pharmaceutical market environment, as the competition in the entire market becomes more and more fierce, pharmaceutical companies have to adjust their business, and the accompanying wave of layoffs is also more and more fierce, not only small companies with weak viability, but also large companies
.
From the perspective of the industry, the trend of layoffs by pharmaceutical companies has just begun
.
Through layoffs, some pharmaceutical companies may be able to quickly reduce operating costs and focus on more core businesses, thus entering a relatively healthy and stable development state
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
